Eloralintide (development code LY3841136) is a selective long-acting amylin receptor agonist developed by Eli Lilly. Unlike Cagrilintide, which binds both amylin and calcitonin receptors, Eloralintide is engineered for amylin receptor selectivity, a design intended to reduce off-target signalling and improve tolerability.
Phase 2 Trial Outcomes
The 48-week, double-blind, placebo-controlled Phase 2 trial enrolled adults with overweight or obesity. Weekly subcutaneous Eloralintide produced dose-dependent weight reduction with a tolerability profile distinct from the GLP-1 class: gastrointestinal adverse events were reported less frequently than with incretin monotherapy, with nausea predominantly mild and transient in the first weeks of treatment.
Mechanism: Amylin Selectivity
Amylin is a 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells. It modulates gastric emptying, suppresses post-prandial glucagon, and acts centrally on the area postrema to reduce food intake. Selective amylin receptor agonism, distinct from dual amylin and calcitonin receptor agonism, is hypothesised to deliver appetite suppression with a cleaner downstream profile [1].
Eloralintide plus Tirzepatide
A separate combination arm (NCT06916065 program) evaluated Eloralintide co-administered with Tirzepatide. The amylin plus dual incretin combination is the leading non-triple-agonist candidate for next-generation obesity therapy, with mechanistic complementarity across appetite, gastric emptying, and energy expenditure pathways.
Eloralintide vs Cagrilintide
- Receptor selectivity: Eloralintide targets amylin receptors selectively; Cagrilintide engages amylin and calcitonin receptors.
- Half-life: Both are engineered for once-weekly administration through fatty acid acylation.
- Combination data: Cagrilintide has the most mature combination dataset (CagriSema with Semaglutide); Eloralintide combination data with Tirzepatide is now emerging.
Research Procurement Considerations
Eloralintide is not commercially available as a research peptide at the time of writing. Laboratories interested in amylin pathway research currently work with Cagrilintide or Cagrilintide + Semaglutide blends as the closest available analogues. When Eloralintide reaches research-grade supply, verify HPLC purity at 99% or above, mass spectrometry confirmation of the acylated structure, and endotoxin below 0.5 EU/mg for cell-based work.
References
- [1] Eloralintide Phase 2 trial publication, 2026.
- [2] ClinicalTrials.gov NCT06916065, Eloralintide with Tirzepatide in overweight or obesity.